We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for vorasidenib citrate (Servier Laboratories (Aust) Pty Ltd)
Active ingredients
vorasidenib citrate
Date of review outcome
Lapse date
Type
Priority Review
Indication
Treatment of predominantly non-enhancing astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH-1) mutation or isocitrate dehydrogenase-2 (IDH-2) mutation in adults and paediatric patients 12 years and older following surgical intervention
Therapeutic area
Oncology